Close

GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation (“Alcami”), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison Dearborn Partners (“MDP”) and Ampersand Capital Partners (“Ampersand”).

Headquartered in North Carolina, Alcami operates five campuses across the United States, which support sterile fill-finish and oral solid dose drug product manufacturing; formulation development; lab services; and cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals, and materials.

Patrick Walsh, Chairman and CEO of Alcami, welcomes Jim Datin, Mike Mortimer, Alan MacKay, Jonathon Maschmeyer, Natasha Latif, and Bill Sharbaugh to the Alcami Board of Directors.

GHO Capital and The Vistria Group have acquired a 50/50 controlling interest in Alcami from funds affiliated with MDP and Ampersand. Ampersand and Alcami Management have reinvested significant equity as part of the acquisition. The financial terms of the transaction were not disclosed.

 

Latest stories

Related stories

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back